Cannon Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Cannon Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.67M	Buy	+18,369	New	+$3.69M	2.13%	15

Other funds holding IBB

Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return

MinichMacGregor Wealth Management Saratoga Springs, New York $620M AUM 32.35% 1-Year Est. Return

Old National Bancorp Evansville, Indiana $5.07B AUM 22.07% 1-Year Est. Return

Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.18B AUM 27.44% 1-Year Est. Return

DRP

Decker Retirement Planning Levi, Utah $302M AUM 70.25% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Cannon Advisors's IBB Position: Q3 2026 in Review

Cannon Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q3 2026: 18,369 shares worth $3.67M. The stake represents 2.13% of the portfolio and ranks #15 among its holdings.

202 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

Cannon Advisors held 18,369 shares of iShares Biotechnology ETF worth $3.67M as of Q3 2026.
iShares Biotechnology ETF was a new Cannon Advisors position in Q3 2026.
iShares Biotechnology ETF made up 2.13% of Cannon Advisors's portfolio in Q3 2026, its #15 holding.
202 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Cannon Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.